Business
Faron´s Annual Report 2019 published
Faron´s Annual Report 2019 published.
About this update from Faron Pharmaceuticals Oy
[{"type":"text","content":"\n \n \n RNS Number : 5169H\n Faron Pharmaceuticals Oy\n 25 March 2020\n \n \n \n \n Faron Pharmaceuticals Oy\n \n \n (\"Faron\" or the \"Company\")\n \n \n \n \n \n Faron´s Annual Report 2019 published\n \n \n \n \n \n \n \n \n Company announcement, 25 March 2020 at 9.00 AM (EET)\n \n \n \n \n \n \n \n TURKU - FINLAND \n \n - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, announces that its Annual Report for the year 2019 has been published today. \n \n \n \n \n \n Faron Pharmaceuticals´ Annual Report 2019 and financial statements for the accounting period 1 January - 31 December 2019 have been published in English and its financial statements in Finnish, on the Company's website https://www.faron.com/investors/results. \n \n \n \n \n \n \n \n \n For more information please contact:\n \n \n \n \n \n Faron Pharmaceuticals Oy\n \n \n Dr Markku Jalkanen, Chief Executive Officer\n \n \n \n \n [email protected]\n \n \n \n \n \n \n \n \n Panmure Gordon (UK) Limited, Nomad and Broker\n \n \n Emma Earl, Freddy Crossley (Corporate Finance)\n \n \n James Stearns (Corporate Broking)\n \n \n Phone: +44 207 886 2500\n \n \n \n \n \n Sisu Partners Oy, Certified Adviser on Nasdaq First North\n \n \n Juha Karttunen, Jussi Majamaa\n \n \n Phone: +358 (0)40 555 4727\n \n \n \n \n \n Consilium Strategic Communications\n \n \n Mary-Jane Elliott, David Daley, Lindsey Neville\n \n \n Phone: +44 (0)20 3709 5700\n \n \n E-mail: \n \n \n [email protected]\n \n \n \n \n \n \n \n About Faron Pharmaceuticals Ltd \n \n \n Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen, its precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. Currently in phase I/II clinical development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, Clevegen has ...